Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years' discoveries and developments.
Knowledge of the molecular mechanisms on malignant tumors is very critical for the development of new treatment strategies like molecularly targeted therapies. In last 5 years, many investigations suggest that stathmin is over-expressed in a variety of human malignant tumors, and potentially promotes the occurrence and development of tumors. Rather, down-regulation of stathmin can reduce cell proliferation, motility and metastasis and induce apoptosis of malignant tumors. Thus, a stathmin antagonist, such as a specific inhibitor (antibody, small molecule compound, peptide, or siRNA), may be a novel strategy of molecular targeted therapy. This review summarizes the research progress of recent 5 years on the role of stathmin in tumorigenesis, the molecular mechanisms and development of anti-stathmin treatment, which suggest that continued investigations into the function of stathmin in the tumorigenesis could lead to more rationally designed therapeutics targeting stathmin for treating human malignant tumors.
Department of Respiratory Medicine, First Affiliated Hospital, Xi'an Medical University, Xi'an, China. research568rbx@yeah.net.
Rong
R
Biaoxue
Department of Respiratory Medicine, Gansu Provincial Hospital, Lanzhou, China.
Cai
C
Xiguang
Department of Respiratory Medicine, Gansu Provincial Hospital, Lanzhou, China.
Liu
L
Hua
Department of Respiratory Medicine, Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Yang
Y
Shuanying
Anticancer therapy; Cancer; Drug target; Molecular targeted therapy; Stathmin
J Biol Chem. 2010 Apr 9;285(15):11667-80
20145240
Curr Cancer Drug Targets. 2011 Nov;11(9):1082-97
21933105
Cancer Gene Ther. 2015 Apr;22(3):115-21
25572118
J Virol. 2015 Jan;89(1):35-47
25320307
Oncol Rep. 2012 Mar;27(3):714-8
22038457
Acta Biochim Biophys Sin (Shanghai). 2014 Dec;46(12):1034-40
25348735
J Gastroenterol Hepatol. 2014 Sep;29(9):1685-91
24720379
J Gastroenterol Hepatol. 2014 May;29(5):944-50
24372619
PLoS One. 2012;7(3):e33919
22470493
Mol Biol Cell. 2013 Dec;24(24):3819-31
24152729
Leuk Res. 2014 Feb;38(2):251-7
24355524
Biochim Biophys Acta. 2012 Nov-Dec;1819(11-12):1164-72
23000483
Mutat Res. 2011 Jun 17;722(2):154-64
20816848
J Transl Med. 2014 May 31;12:154
24885363
Mol Med Rep. 2014 Dec;10(6):2985-92
25310700
Oncotarget. 2015 Oct 6;6(30):29573-84
26356819
Asian Pac J Cancer Prev. 2014;15(8):3613-8
24870766
Curr Mol Med. 2013 Dec;13(10):1603-12
24206132
Cancer Biother Radiopharm. 2016 Mar;31(2):37-43
26881937
Int J Mol Sci. 2015 Jan 28;16(2):2942-55
25636036
Oncoscience. 2015 Mar 23;2(3):294-308
25897432
J Surg Oncol. 2011 Jun 1;103(7):704-15
21360534
Biochim Biophys Acta. 2015 Mar;1853(3):583-93
25523139
Tumour Biol. 2014 Mar;35(3):2619-29
24218338
Am J Surg Pathol. 2013 Jan;37(1):89-97
23211296
Cancer Biother Radiopharm. 2014 Nov;29(9):376-86
25379611
Expert Rev Anticancer Ther. 2008 Sep;8(9):1461-70
18759697
Oncol Rep. 2013 Feb;29(2):419-24
23229199
J Proteome Res. 2012 Feb 3;11(2):1433-45
22181002
Tumour Biol. 2016 Jul;37(7):9951-8
26815505
Oncol Res. 2016;23 (1-2):35-41
26802649
Cancer Gene Ther. 2013 May;20(5):298-307
23618950
Br J Cancer. 2014 Sep 9;111(6):1180-7
25072257
Invest Ophthalmol Vis Sci. 2011 Jul 23;52(8):5441-8
21546534
Mol Cancer Res. 2014 Dec;12(12):1717-28
25063586
PLoS One. 2014 Feb 25;9(2):e90141
24587245
Asian Pac J Cancer Prev. 2012;13(6):2967-71
22938491
PLoS One. 2012;7(10):e46173
23071542
Clin Cancer Res. 2013 May 1;19(9):2331-41
23538402
Mol Med Rep. 2015 May;11(5):3330-6
25607713
Tumour Biol. 2013 Oct;34(5):3137-45
23760979
Mol Carcinog. 2010 May;49(5):476-87
20232364
Lab Invest. 2015 Jan;95(1):56-64
25384122
Gynecol Oncol. 2011 Oct;123(1):5-12
21683992
Cancer. 2012 Oct 1;118(19):4660-9
22359235
Curr Mol Med. 2014 Mar;14(3):328-39
24588766
Cell Cycle. 2016 May 2;15(9):1288-94
26986925
Cancer Gene Ther. 2012 Apr;19(4):271-81
22281755
Cell Signal. 2009 May;21(5):695-703
19162178
Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12851-6
21768358
Adv Biol Regul. 2015 Jan;57:1-9
25294678
Hepatobiliary Pancreat Dis Int. 2014 Aug;13(4):386-94
25100123
Int J Clin Exp Med. 2015 Apr 15;8(4):6502-9
26131279
Tumour Biol. 2015 Jan;36(1):399-408
25266798
Cell Signal. 2014 Jul;26(7):1532-8
24686088
Ann Surg Oncol. 2013 Nov;20(12):4041-54
22911364
Cell Oncol (Dordr). 2014 Feb;37(1):53-67
24306928
J Cell Biochem. 2011 Dec;112(12):3621-9
21809374
Neurobiol Learn Mem. 2015 Oct;124:52-61
26211874
Mol Cancer Res. 2015 Jul;13(7):1106-18
25824152
Cancer Sci. 2014 Jun;105(6):690-6
24708177
ISRN Pharmacol. 2013 May 30;2013:279593
23819061
Oncogene. 2014 Feb 13;33(7):882-90
23396365
Genet Mol Res. 2015 Dec 29;14 (4):18695-702
26782519
J Immunol. 2013 Dec 15;191(12 ):6250-60
24227773
Clin Chim Acta. 2012 Oct 9;413(19-20):1641-6
22626996
Anticancer Res. 2014 Aug;34(8):4217-21
25075050
Oncogene. 2013 Mar 7;32(10):1330-7
22665054
Proteome Sci. 2016 Mar 11;14:6
26973435
PLoS One. 2014 Oct 06;9(10):e109750
25285524
DNA Cell Biol. 2011 Sep;30(9):715-26
21612405
Tumour Biol. 2015 Sep;36(10):7797-806
25944168
Cancer Biother Radiopharm. 2013 Jun;28(5):398-405
23496232
Mol Med Rep. 2014 Nov;10(5):2613-20
25215905
J Neurooncol. 2013 Dec;115(3):381-90
24043603
Neoplasma. 2014;61(2):144-52
24299310
Expert Opin Ther Targets. 2011 Nov;15(11):1249-66
21978024
Nat Commun. 2014 Sep 04;5:4497
25187177
J Transl Med. 2013 Sep 16;11:212
24040910
J Bone Oncol. 2012 Jul 18;1(2):40-6
26909254
J Cell Mol Med. 2014 May;18(5):811-23
24628949
Tumour Biol. 2015 Sep;36(9):7195-204
25894372
J Urol. 2011 Nov;186(5):2094-100
21944130
Oncogene. 2016 Oct 13;35(41):5412-5421
27041561
EMBO Mol Med. 2013 May;5(5):707-22
23610071
BMC Cancer. 2016 Feb 15;16:101
26878873
Int J Oncol. 2012 Jun;40(6):1889-99
22378487
Cancer Sci. 2012 Jun;103(6):993-9
22417000
Cell Cycle. 2014;13(19):3100-11
25486569
Oncol Rep. 2013 May;29(5):2019-24
23483142